- Home
- GIGM vs INDP Comparison
GIGM vs INDP Comparison
Compare GIGM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | INDP |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 4.0M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | INDP |
|---|---|---|
| Price | $1.47 | $2.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 1.8M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $1.65 |
| 52 Week High | $1.89 | $47.60 |
Technical Indicators
Market Signals| Indicator | GIGM | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 51.49 |
| Support Level | $1.48 | $2.46 |
| Resistance Level | $1.55 | $3.06 |
| Average True Range (ATR) | 0.05 | 0.30 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 18.93 | 51.08 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.